Top Markets
#1 Black Phoenix Black Phoenix +736.58%
#2 Islamic Coin Islamic Coin +146.19%
#3 THORChain THORChain +26.54%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.17%
#5 MiL.k Alliance MiL.k Alliance +22.54%
#6 THORChain Yield THORChain Yield +19.87%
#7 Bless Bless +18.53%
#8 TENDIES TENDIES +16.52%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +14.30%
#10 The Black Bull The Black Bull +11.04%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Rang in Aktien #5120
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Aktienkurs
$58.70
Zuletzt synchronisiert: 2024-01-23
Marktkapitalisierung
$2.98B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Mirati Therapeutics, Inc. (MRTX)

Kategorie

Healthcare
P/B-Verhältnis für Mirati Therapeutics, Inc. (MRTX)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Mirati Therapeutics, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Mirati Therapeutics, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH